Overall Score

Base Case

ARCT remains a cash-rich, low-debt biotech with a strong current ratio of 5.88 and cash per share of 6.74.

Gross margin is still very high at 83.2%, but profitability remains deeply negative with operating margin at -433.4% and net margin at -391.9%.

Valuation remains mixed: EV/Sales is 5.19 and price-to-book is 1.70, while free cash flow and earnings remain negative.

Bull Case

A strong balance sheet and net current asset value of 144.7M provide downside support if execution improves.

High gross margin and low leverage could allow operating leverage to emerge if R&D spending translates into commercial progress.

The market may continue to reward optionality given the company’s cash position and biotech pipeline potential.

Bear Case

Persistent losses, negative free cash flow, and a cash conversion cycle of -375.0 days remain the main downside risks.

R&D intensity is still very high at 362.1% of revenue, which keeps near-term earnings pressure elevated.

If pipeline progress stalls, the current valuation could compress despite the strong liquidity profile.